Edition:
India

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

3.53USD
11 Aug 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.53
Open
$3.65
Day's High
$3.65
Day's Low
$3.47
Volume
685,225
Avg. Vol
788,651
52-wk High
$4.79
52-wk Low
$1.82

Summary

Name Age Since Current Position

Garo Armen

66 1994 Chairman of the Board, Chief Executive Officer, Co-Founder

Jennifer Buell

45 2019 President, Chief Operating Officer

Christine Klaskin

54 2018 Chief Accounting Officer, Vice President - Finance

Evan Kearns

39 2018 Chief Compliance Officer, Vice President, General Counsel, Corporate Secretary

Donald Vidic

2019 Vice President - Head of Commercial

Timothy Wright

62 2009 Lead Independent Director

Brian Corvese

62 2007 Independent Director

Allison Jeynes-Ellis

54 2018 Independent Director

Wadih Jordan

85 2003 Independent Director

Ulf Wiinberg

61 2016 Independent Director

Biographies

Name Description

Garo Armen

Dr. Garo H. Armen Ph.D. serves as Chairman of the Board, Chief Executive Officer, Co-Founder of the Company. Dr. Armen is Chairman and Chief Executive Officer of Agenus Inc., which he co-founded in 1994. Dr. Armen brings to our Board a deep historical and practical knowledge of the business of the Company and its technologies, as well as years of expertise in the financial and biopharmaceutical arenas. From mid-2002 through 2004, he was Chairman of the Board of Directors for the biopharmaceutical company Elan Corporation, plc which he helped restructure. Dr. Armen currently serves as non-executive Chairman of the Board of Directors of Protagenic Therapeutics, Inc., a publicly held biotechnology company. Dr. Armen is also the founder and Chairman of the Children of Armenia Fund, a philanthropic organization established in 2000 that is dedicated to the positive development of the children and youth of rural Armenia. He holds a Ph.D. degree in physical organic chemistry from the City University of New York.

Jennifer Buell

Dr. Jennifer S. Buell serves as President, Chief Operating Officer of the Company. From November 2013 to July 2016, Dr. Buell was the Company’s Vice President, Research and Development Operations and Program Management. From July 2016 to November 2017, she was the Company’s Vice President, Research and External Affairs, and from November 2017 to November 2018, she served as the Chief Communications and External Affairs Officer. Dr. Buell obtained her PhD in Cellular, Biochemical, and Molecular Biochemistry with an MS in Biostatistics from Tufts University.

Christine Klaskin

Ms. Christine M. Klaskin is the Principal Accounting Officer of Agenus Inc. Ms. Klaskin has been Vice President, Finance since October 2006. Since joining Agenus Inc. in 1996 as finance manager, Ms. Klaskin has held various positions within the finance department and has been involved in all equity and debt offerings of the Company including its IPO. Ms. Klaskin is currently a member of the board of directors of American DG Energy Inc. Prior to joining Agenus, Ms. Klaskin was employed by Arthur Andersen as an audit manager. Ms. Klaskin received her Bachelor of Accountancy from The George Washington University.

Evan Kearns

Mr. Evan Kearns J.D. serves as Chief Compliance Officer, Vice President, General Counsel, Corporate Secretary of the Company. Mr. Kearns joined Agenus in 2014 as our Corporate Counsel and became our Associate General Counsel in 2015. Prior to Agenus, Mr. Kearns worked at the law firm Goodwin Procter LLP. Mr. Kearns holds a B.A. in Economics from Colby College and a J.D. degree from the University of Toledo College of Law.

Donald Vidic

Mr. Donald Vidic serves as Vice President - Head of Commercial of the Company. Don has 30 years of expertise in pharma distribution, managed care, as well as physician and pharmacy services. For the majority of that time, he has been committed to commercial endeavors that provide access to all patients who require complex medications that are difficult to access. Prior to joining Agenus, Don served as the Chief Pharmacy and Growth Officer at Alliance Rx Walgreens Prime (a division of Walgreens Boots Alliance), where he was responsible for pharmacy and manufacturer services, clinical services, regulatory compliance as well as marketing and sales. Preceding his 10 years at Walgreens where he consistently took on increasing responsibilities, he was the Vice President and General Manager of McKesson Specialty Pharmacy. Don is a registered Pharmacist having graduated from the University of Pittsburgh with a BS in Pharmacy in 1989. Don also attained his Masters in Business Administration from Waynesburg University.

Timothy Wright

Mr. Timothy R. Wright serves as Lead Independent Director of the Company. Mr. Wright is the Chief Executive Officer of MiMedX Group, Inc. (“MiMedX”), a position that he has held since May 2019. MiMedX is an advanced wound care and emerging therapeutic biologics company. Mr. Wright has also been a Director of MiMedX since June 2019. Mr. Wright also serves as a Partner at Signal Hill Advisors, LLC, a position he has held since February 2011. Mr. Wright also serves as chairman of The Ohio State University Comprehensive Cancer Center Drug Development Institute, and director of the Ohio State University Innovation Foundation. Mr. Wright was the President and Chief Executive Officer and a director of M2Gen Corp., a privately held health informatics company, between July 2017 and September 2018. From April 2015 through July 2017, Mr. Wright was the Executive Vice President, Mergers and Acquisitions, Strategy and Innovation at Teva Pharmaceuticals Industries Ltd. From September 2013 to March 2015, Mr. Wright served as head of The Ohio State University Technology Transfer Office. From July 2011 to July 2012, Mr. Wright served as Chairman, Interim CEO, and a member of the Board of Directors of Curaxis Pharmaceuticals Corporation, a research based company dedicated to finding cures for age-related diseases, including Alzheimer’s disease and cancer. Prior to Mr. Wright’s tenure at Curaxis, the company had been experiencing financial difficulties and, as a result, Curaxis filed for Chapter 11 bankruptcy in July 2012. Prior to that, Mr. Wright served as President of the Imaging Solutions and Pharmaceutical Products Sector of Covidien from February 2007 until December 2010. Mr. Wright brings to our Board over 30 years of global pharmaceutical industry experience in general management, product development, and commercialization as well as business restructuring and transaction experience. Mr. Wright earned his bachelor’s degree from The Ohio State University.

Brian Corvese

Mr. Brian J. Corvese serves as Independent Director of the Company. Since 1999, Mr. Corvese has been the President and Founder of Vencor Capital (“Vencor”), a private equity firm with telecommunications and technology investments in the Middle East and Mediterranean regions. Prior to working at Vencor, Mr. Corvese worked on investments in the U.S. and global equity markets as a Managing Director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management (“Chancellor”), a $25 billion money management firm. While at Chancellor, Mr. Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert (“Drexel”) as an equity analyst following the chemical and specialty chemical industries and participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. Mr. Corvese currently serves on the Board of Directors of the National Telecommunications Corporation, based in Cairo, Egypt, and Protagenic Therapeutics based in Ontario, Canada. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School. With over 30 years of experience in the financial industry, Mr. Corvese brings substantial financial expertise to our Board.

Allison Jeynes-Ellis

Dr. Allison M. Jeynes-Ellis M.D. serves as Independent Director of the Company. Dr. Jeynes-Ellis is a trained clinician with more than 25 years of senior leadership experience in the pharmaceutical industry. Dr. Jeynes-Ellis is the Chief Executive Officer and a Director of Avillion LLP (“Avillion”), a London-based drug development company. Prior to her current position as CEO, Dr. Jeynes-Ellis served as Avillion’s Chief Medical Officer from December 2012 to January 2014. Before her tenure at Avillion, Dr. Jeynes-Ellis worked in senior roles at Wyeth, Bristol-Myers Squibb, and Novartis. Her previous affiliations also include Cambridge Antibody Technology and Genentech, government bodies and medical charities. She has managed teams focusing on global clinical development projects that have led to drug approvals in Europe and the United States, across a range of therapeutic areas. Dr. Jeynes-Ellis currently serves as a Senior Advisor to Blackstone Life Sciences.

Wadih Jordan

Mr. Wadih Jordan serves as Independent Director of the Company. Mr. Jordan was most recently the founder and President of NearEast Enterprise, L.L.C. from 2011 to April 2015, a company that marketed pharmaceuticals in Near East markets, including Lebanon, Turkey, Saudi Arabia, Egypt, and the Gulf countries. From 1995 to 2011, Mr. Jordan served as President of NearEast Pharma LLC, a company that provided pharmaceutical, biotechnology and equipment for pharmaceutical industries to the Near East and Middle East markets. From 1993 to 1995, Mr. Jordan served as a Vice President of Cyanamid International, a research-based life sciences company, and from 1976 to 1993, Mr. Jordan served as a Managing Director within Cyanamid International. From December 2003 to December 2015, Mr. Jordan was a trustee of the Board of Directors of the Lebanese American University, located in Beirut, Lebanon, and incorporated under the Board of Regents in New York State. Mr. Jordan received a bachelor’s degree in agriculture at the American University of Beirut, Lebanon, and a certificate in international business from Columbia University. Mr. Jordan brings to our Board years of expertise in both the biotechnology/pharmaceutical and international arenas.

Ulf Wiinberg

Mr. Ulf Wiinberg serves as Independent Director of the Company. Mr. Wiinberg has almost 20 years of senior leadership experience, most recently serving as Chief Executive Officer of H. Lundbeck A/S (“Lundbeck”) from June 2008 to December 2014. Lundbeck is a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders. He previously served on the boards of several health care industry associations and held multiple executive roles at Wyeth, one of the world’s largest research-driven pharmaceutical companies that was acquired by Pfizer in 2009. He served as President of Wyeth Europe, Africa and Middle East; President of Consumer Healthcare; Managing Director of Wyeth UK, and in various commercial positions. Mr. Wiinberg currently serves on the boards of UCB SA, a global biopharmaceutical company based in Belgium, Avillion LLP (Chairman), a London-based drug development company, Hansa Medical AB (Chairman), a Swedish biopharmaceutical company, and Alfa Laval AB, a Swedish industrial company. Mr. Wiinberg brings to our Board years of experience in the biotechnology, pharmaceutical and healthcare industries internationally.

Basic Compensation

Name Fiscal Year Total

Garo Armen

9,937,040

Jennifer Buell

2,385,370

Christine Klaskin

497,477

Evan Kearns

1,610,580

Donald Vidic

--

Timothy Wright

562,141

Brian Corvese

662,141

Allison Jeynes-Ellis

407,935

Wadih Jordan

457,141

Ulf Wiinberg

559,917
As Of  31 Dec 2019